JEROME B. ZELDIS, M.D., PH.D. - Corporate Board Profile

PTC THERAPEUTICS, INC.

Filing Date	Source Excerpt
2014-04-28	Jerome B. Zeldis, M.D., Ph.D. Director Age 63 Dr. Zeldis has served as a member of our Board since September 2012. Dr. Zeldis currently serves as the Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he has been employed since 1997. He previously served as Celgene's Senior Vice President of Clinical Research and Medical Affairs. Previously, Dr. Zeldis served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received an A.B. and M.S. from Brown University and a M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University. Dr. Zeldis has served on the board of directors of Soligenix, Inc., a public biopharmaceutical company, since June 2011, and on the board of directors of Alliqua, Inc., a public biomedical company, since May 2012. We believe that Dr. Zeldis is qualified to serve on our Board because of his extensive executive leadership experience and knowledge of our industry.
2015-04-28	Jerome B. Zeldis, M.D., Ph.D. Director Age 64 Dr. Zeldis has served as a member of our Board since September 2012. ... 2014 Director Compensation Table shows Jerome Zeldis received total compensation of $389,424.
2016-04-28	Jerome B. Zeldis, M.D., Ph.D. Nominating and Corporate Governance Committee Age 65 Dr. Zeldis has served as a member of our Board since September 2012. Dr. Zeldis currently serves as the Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he has been employed since 1997. He previously served as Celgene's Senior Vice President of Clinical Research and Medical Affairs. Previously, Dr. Zeldis served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received an A.B. and M.S. from Brown University and a M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University. Dr. Zeldis has served on the board of directors of several public companies, including Soligenix, Inc., a biopharmaceutical company since 2011, Alliqua, Inc., a biomedical company since 2012, and BioSig Technologies, Inc., a medical device company since July 2015. In addition, Dr. Zeldis founded and serves as the chairman of Trek Therapeutics, a private biomedical company, since November 2014. We believe that Dr. Zeldis is qualified to serve on our Board because of his extensive executive leadership experience and knowledge of our industry. 2015 Director Compensation Table: Jerome B. Zeldis, M.D., Ph.D. Fees earned or paid in cash $35,000 Option awards $359,801 All other compensation $0 Total $394,801
2016-04-28	Jerome B. Zeldis, M.D., Ph.D. Nominating and Corporate Governance Committee Age 65 Dr. Zeldis has served as a member of our Board since September 2012. Dr. Zeldis currently serves as the Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he has been employed since 1997. He previously served as Celgene's Senior Vice President of Clinical Research and Medical Affairs. Previously, Dr. Zeldis served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received an A.B. and M.S. from Brown University and a M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry) from Yale University. Dr. Zeldis has served on the board of directors of several public companies, including Soligenix, Inc., a biopharmaceutical company since 2011, Alliqua, Inc., a biomedical company since 2012, and BioSig Technologies, Inc., a medical device company since July 2015. In addition, Dr. Zeldis founded and serves as the chairman of Trek Therapeutics, a private biomedical company, since November 2014. We believe that Dr. Zeldis is qualified to serve on our Board because of his extensive executive leadership experience and knowledge of our industry. 2015 Director Compensation Table: Jerome B. Zeldis, M.D., Ph.D. Fees earned or paid in cash $35,000 Option awards $359,801 All other compensation $0 Total $394,801
2017-04-28	Dr. Zeldis has served as a member of our Board since September 2012. Dr. Zeldis currently serves as the Chief Medical Officer of Sorrento Therapeutics, Inc., a public clinical-stage biopharmaceutical company. Dr. Zeldis currently serves on the Nominating and Corporate Governance Committee.
2018-04-30	Jerome B. Zeldis, M.D., Ph.D. Audit Committee Nominating and Corporate Governance Committee 68 Dr. Zeldis has served as a member of our Board since September 2012... 2017 Director Compensation Table: Jerome Zeldis, M.D., Ph.D. Fees earned or paid in cash $52,462, Option awards $87,800, Total $140,262.
2019-04-25	Jerome Zeldis, M.D., Ph.D. Nominating and Corporate Governance Committee 69 Dr. Zeldis has served as a member of our Board since September 2012. 2018 DIRECTOR COMPENSATION The following table sets forth information regarding compensation awarded to, earned by or paid to our directors, other than Dr. Peltz, during 2018: Name Fees earned or paid in cash ($) Option awards ($)(1) All other compensation ($) Total ($) Jerome Zeldis, M.D., Ph.D. 61,000 169,537 — 230,537
2020-04-27	Jerome B. Zeldis, M.D., Ph.D. Nominating and Corporate Governance Committee 70 Dr. Zeldis has served as a member of our Board since September 2012. ... During 2019, our non-employee directors were compensated for their service as directors, including as members of the various committees of our Board, as follows: ... Jerome B. Zeldis, M.D., Ph.D. $53,000 fees earned or paid in cash, $276,355 option awards, total $329,355.
2021-04-29	Dr. Zeldis has served as a member of our Board since September 2012. Dr. Zeldis currently serves as the Executive Vice President and Head of Research and Development of NexImmune, Inc., a clinical-stage biotechnology company. From August 2016 through March 2020, Dr. Zeldis serves as the Chief Medical Officer of Sorrento Therapeutics, Inc., a public clinical-stage biopharmaceutical company. From August 2017 through September 2018, Dr. Zeldis served as the Chief Medical Officer of Celularity, Inc., a biotechnology company. Prior to joining Sorrento, Dr. Zeldis served as Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation, a public biopharmaceutical company, where he had been employed since 1997. He previously served as Celgene's Senior Vice President of Clinical Research and Medical Affairs. Previously, Dr. Zeldis served as Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received an A.B. and M.S. from Brown University and a M.Phil., M.D. and Ph.D. in Molecular Biophysics and Biochemistry from Yale University. Dr. Zeldis has served on the board of directors of Soligenix, Inc., a Nasdaq-listed biopharmaceutical company, since 2011; and has previously served on the board of directors of several public companies including; BioSig Technologies, Inc., a Nasdaq-listed diagnostic company, from 2015 to 2017 and from 2019 to 2020; Alliqua BioMedical, Inc., a Nasdaq-listed biomedical company, from 2011 to 2017; MetaStat, Inc., a medical device company traded on the OTCQB, from 2016 to 2019; and Kalytera Therapeutics, Inc., a pharmaceutical company traded on the TSXV, from 2015 to 2017. We believe that Dr. Zeldis is qualified to serve on our Board because of his executive leadership experience, his knowledge of the biopharmaceutical industry, his extensive role in drug development and clinical studies as well as his directorships in other life science companies.
2023-04-26	Jerome B. Zeldis, M.D., Ph.D. has served as a member of our Board since September 2012. Dr. Zeldis served as the Executive Vice President and Head of Research and Development of NexImmune, Inc., a Nasdaq-listed clinical-stage biotechnology company from January 2021 to March 2023. ... We believe that Dr. Zeldis is qualified to serve on our Board because of his executive leadership experience, his knowledge of the biopharmaceutical industry, his extensive role in drug development and clinical studies as well as his directorships in other life science companies.